SGEN - シアトル・ジェネティクス (Seattle Genetics Inc.)

SGENのニュース

   Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference  2020/09/03 12:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the virtual Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 3:30 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Seattle Genetics Seattle Genetics, Inc. is a global biotechnology company t
   Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin)  2020/08/27 12:10:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commission conditional marketing authorisation for GSK’s BLENREP™ (belantamab mafodotin), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics’ proprietary technology. BLENREP was developed and will be commercialized by GSK. In addition to the milestone payment, Seattl
   Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020  2020/08/27 12:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the presentation of new data from its broad pipeline of marketed and investigational therapies at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, taking place September 19-21. Twelve abstracts, including a late-breaking abstract accepted for oral presentation featuring data from the positive tisotumab vedotin phase 2 innovaTV 204 clinical trial in recurrent or metastatic cervical cancer
   Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors  2020/08/18 12:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Ted W. Love, M.D., has been appointed to the company’s Board of Directors. Dr. Love has more than 25 years of global experience in the healthcare and biotechnology/pharmaceutical industry and currently serves as President and Chief Executive Officer of Global Blood Therapeutics. “We are pleased to welcome Ted to our Board of Directors given his distinguished industry expertise and leadership,” said Clay S
   Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative  2020/08/12 12:00:00 Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with tras
   Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference  2020/09/03 12:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the virtual Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 3:30 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Seattle Genetics Seattle Genetics, Inc. is a global biotechnology company t
   Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin)  2020/08/27 12:10:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commission conditional marketing authorisation for GSK’s BLENREP™ (belantamab mafodotin), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics’ proprietary technology. BLENREP was developed and will be commercialized by GSK. In addition to the milestone payment, Seattl
   Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020  2020/08/27 12:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the presentation of new data from its broad pipeline of marketed and investigational therapies at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, taking place September 19-21. Twelve abstracts, including a late-breaking abstract accepted for oral presentation featuring data from the positive tisotumab vedotin phase 2 innovaTV 204 clinical trial in recurrent or metastatic cervical cancer
   Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors  2020/08/18 12:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Ted W. Love, M.D., has been appointed to the company’s Board of Directors. Dr. Love has more than 25 years of global experience in the healthcare and biotechnology/pharmaceutical industry and currently serves as President and Chief Executive Officer of Global Blood Therapeutics. “We are pleased to welcome Ted to our Board of Directors given his distinguished industry expertise and leadership,” said Clay S
   Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative  2020/08/12 12:00:00 Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with tras
   Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative  2020/08/12 12:00:00 Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with tras
   Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval  2020/08/06 12:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline’s (GSK) BLENREP™ (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics’ proprietary technology. BLENREP was developed and will be commercialized by GSK. The approval triggers a $20 million milestone payment and entitles Seattle Genetics to royalties on BLENREP pr
   Seattle Genetics Reports Second Quarter 2020 Financial Results  2020/07/30 20:02:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin-ejfv) and TUKYSA (tucatinib) commercial and development accomplishments, as well as progress with its lead pipeline programs to treat cancer. “We generated record product sales of $240.5 million in the second quarter driven by ADCETRIS, PADCEV and n
   Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation  2020/07/24 12:10:00 Benzinga
Seattle Genetics, Inc’s (NASDAQ: SGEN) stock already reflects the urothelial bladder cancer opportunity, according to Piper Sandler. The sell-side …
   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020  2020/07/09 12:00:00 Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after t

calendar